Denemek ALTIN - Özgür

Indian Genes Could Save the World From Rare Diseases

Mint New Delhi

|

July 09, 2025

India Offers a Treasure Trove of Genetic Data for Researchers to Develop Long-Neglected Therapies

- RAHUL MATTHAN

In an episode of my podcast titled "The Incurable Disease," I told of how a husband and wife with no previous medical training or experience built a genetics laboratory in a bungalow in Bangalore so they could find a treatment for Duchenne's Muscular Dystrophy (DMD) to save their son. As much as this is a story of grit and perseverance, it also shows how far genetic technology has come and how affordable its innovations can now be.

Diseases like DMD are rare medical conditions. They affect a relatively small proportion of the general population. Yet, over 400 million people suffer from more than 7,000 known rare diseases today, with the Global South bearing the bulk of this burden.

While there are treatments for many rare diseases, given the small size of the patient population, pharmaceutical companies cannot achieve the economies of scale needed to make them commercially available. In the 1980s, patient advocacy groups began to draw attention to this, pointing out that research and development (R&D) for rare disease drugs was being discouraged because it wasn't profitable. Since they were being consciously abandoned, they started being called 'orphan drugs.'

Mint New Delhi'den DAHA FAZLA HİKAYE

Mint New Delhi

Mint New Delhi

Andreessen Horowitz to open office in Bengaluru

Andreessen Horowitz, one of the world's biggest venture capital funds, is setting up an office in Bengaluru, multiple people familiar with the development said.

time to read

2 mins

October 10, 2025

Mint New Delhi

Mint New Delhi

Silver ETFs fired up by scarcity, festivals

Silver exchange traded funds or ETFs opened Thursday with a record 10-12% premium to spot prices, underscoring a scramble for the metal as festive buying, industrial use, and investor FOMO (fear of missing out) drove up demand against tight supplies.

time to read

2 mins

October 10, 2025

Mint New Delhi

AI BROKE THE INFO BOTTLENECK, BUT VALUE INVESTING STILL DEPENDS ON INSIGHT

In a Bloomberg column, Guy Spier argues that AI has ended the golden age of value investing by removing the old information edge.

time to read

3 mins

October 10, 2025

Mint New Delhi

Mint New Delhi

TCS preps big pivot to AI, data centres

At least $6 bn investment in 6 yrs; Q2 revenue beats expectations

time to read

3 mins

October 10, 2025

Mint New Delhi

Celebrating the snake in jewellery and art

An exhibition in Mumbai reiterates the power of the serpent motif in ornamentation and shines a light on Jaipur's wealth of gemstones

time to read

2 mins

October 10, 2025

Mint New Delhi

Akasa co-founder Khatri exits after ₹1,200 cr funding

Ex-IAF officer's departure is the first from the founding team since the carrier's 2022 launch.

time to read

1 mins

October 10, 2025

Mint New Delhi

Mint New Delhi

Razorpay to enter four new markets in South-East Asia

Initial public offering (IPO)-bound fintech major Razorpay is planning to expand into three to four new South-East Asian markets by the end of 2026, the firm's top executive told Mint in an interaction.

time to read

1 mins

October 10, 2025

Mint New Delhi

Mint New Delhi

Silver ETFs soar on festive demand, supply crunch

\"In the past three to four weeks, we have seen a surge in silver demand,\" said Vikram Dhawan, head of commodities and fund manager at Nippon India Mutual Fund, which runs the largest gold and silver ETFs in the country.

time to read

2 mins

October 10, 2025

Mint New Delhi

Mint New Delhi

Govt, IBBI eye checks on shady pre-bankruptcy business deals

The Union government is looking to tighten the noose around shady transactions at companies undergoing bankruptcy proceedings committed by previous managements, two people aware of the plans said.

time to read

1 mins

October 10, 2025

Mint New Delhi

American chill pill

America's new 100% pharma tariff, going by a recent post online by US President Donald Trump, was aimed at \"branded or patented\" pharmaceutical products, barring those for which plants were being built in the US.

time to read

1 min

October 10, 2025

Listen

Translate

Share

-
+

Change font size